Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

Adams, 2017, Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases, Gut, 66, 1138, 10.1136/gutjnl-2017-313884 Hadi, 2019, Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: synbiotic supplementation and NAFLD, Crit Rev Food Sci Nutr, 59, 2494, 10.1080/10408398.2018.1458021 Anstee, 2011, Genetics of alcoholic and nonalcoholic fatty liver disease, Semin Liver Dis, 31, 128, 10.1055/s-0031-1276643 Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41 Wong, 2012, Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography, Gut, 61, 409, 10.1136/gutjnl-2011-300342 Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x Younossi, 2011, Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008, Clin Gastroenterol Hepatol, 9, 10.1016/j.cgh.2011.03.020 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 643, 10.1016/j.cgh.2014.04.014 Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367 Vilar-Gomez, 2018, Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers, J Hepatol, 68, 305, 10.1016/j.jhep.2017.11.013 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Ratziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084 Boyle, 2019, Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease, JHEP Rep, 1, 188, 10.1016/j.jhepr.2019.06.004 2018 Nielsen, 2013, The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters, Am J Transl Res, 5, 303 Bril, 2019, Use of plasma fragments of propeptides of Type III, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes, Diabetes Care, 42, 1348, 10.2337/dc18-2578 Ratziu, 2020, Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study, Hepatology, 72, 892, 10.1002/hep.31108 Harrison, 2020 Sanyal, 2019, Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial, Lancet, 392, 2705, 10.1016/S0140-6736(18)31785-9 Labenz, 2018, Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany, Aliment Pharmacol Ther, 48, 1109, 10.1111/apt.14976 Daniels, 2019, ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis, Hepatology, 69, 1075, 10.1002/hep.30163 2012 2009 BS EN ISO 23640:2015 In vitro diagnostic medical devices. Evaluation of stability of in vitro diagnostic reagents. 2005 2014 2010 DeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595 Bunn, 2020 Maintainer, 2020 Robin, 2011, pROC: an open-source package for R and S+ to analyze and compare ROC curves, BMC Bioinformatics, 12, 77, 10.1186/1471-2105-12-77 2018 Wong, 2018, Noninvasive biomarkers in NAFLD and NASH — current progress and future promise, Nat Rev Gastroenterol Hepatol, 15, 461, 10.1038/s41575-018-0014-9 Karsdal, 2020, Collagen biology and non-invasive biomarkers of liver fibrosis, Liver Int, 40, 736, 10.1111/liv.14390 Luo, 2018, An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis, Sci Rep, 8, 12414, 10.1038/s41598-018-30457-y Huber, 2019, Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program, Aliment Pharmacol Ther, 50, 930, 10.1111/apt.15427 Leeming, 2017, Plasma collagen type III (PRO-C3) levels associate with severity of histological features of non-alcoholic steatohepatitis and fibrosis within the screening population from the CENTAUR study, NASH Biomarkers Work Harrison, 2020, NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis, Hepatology, 71, 1198, 10.1002/hep.30590 Harrison, 2018, NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 391, 1174, 10.1016/S0140-6736(18)30474-4 Hartman, 2020, Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes, Diabetes Care, 43, 1352, 10.2337/dc19-1892 Lichtinghagen, 2013, The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values, J Hepatol, 59, 236, 10.1016/j.jhep.2013.03.016 The Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project. https://litmus-project.eu/. Harrison, 2019, Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 394, 2012, 10.1016/S0140-6736(19)32517-6 Eslam, 2021, A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients, Am J Gastroenterol, 116, 984, 10.14309/ajg.0000000000001059 Hirschfield, 2019, Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial, J Hepatol, 70, 483, 10.1016/j.jhep.2018.10.035 Harrison, 2021, Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis, Gastroenterology, 160, 219, 10.1053/j.gastro.2020.08.004